


Nipah vaccine program (mRNA-1215)

Last program update: January 11, 2021

Modality	ID #	Program		Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
 Prophylactic vaccines	mRNA-1273	COVID-19 vaccine							Worldwide BARDA funded
	mRNA-1647	Cytomegalovirus (CMV) vaccine							Worldwide
	mRNA-1653	hMPV/PIV3 vaccine							Worldwide
	mRNA-1893	Zika vaccine							Worldwide BARDA funded
	mRNA-1345	Respiratory syncytial virus (RSV) vaccine							Worldwide
	mRNA-1189	Epstein-Barr virus (EBV) vaccine							Worldwide
	mRNA-1010	Flu vaccine							Worldwide
	mRNA-1020								
	mRNA-1030								
	mRNA-1215	Nipah vaccine							Worldwide NIH funded
mRNA-1644 mRNA-1574	HIV vaccine							Worldwide IAVI/BMGF/NIH funded	
mRNA-1851	Influenza H7N9 vaccine							Worldwide Advancing subject to funding	

Nipah (NiV) virus overview

- NiV, a zoonotic virus transmitted to humans from animals, contaminated food, or through direct human-to-human transmission, causes a range of illnesses including fatal encephalitis
- **Disease burden:**
 - “The worst disease no one has ever heard of”¹
 - Identified as the cause of isolated outbreaks since 2000 in India, Bangladesh, Malaysia, and Singapore and is considered a significant pandemic threat^{2,3}
 - Case fatality rate among infected is estimated at 40-75%^{2,3}
 - Severe respiratory and neurologic complications have no treatment other than intensive supportive care^{1,2}
 - NiV outbreaks cause significant economic burden to impacted regions due to loss of human life and interventions to prevent further spread, e.g. slaughter of infected animals⁴
- **Target population:** Pandemic preparedness
- **Unmet need:** No approved vaccine or treatment

Spectrum of Nipah symptoms²


Mild	Fever Headaches Myalgia Vomiting Sore throat
Severe	Severe respiratory distress Pneumonia Seizures Altered consciousness Encephalitis Coma Death

¹Nipah Virus. Eco Health Alliance. <https://www.ecohealthalliance.org/2018/05/nipah-virus>. Accessed 18Dec2020. ²Nipah virus infection. WHO. https://www.who.int/health-topics/nipah-virus-infection#tab=tab_1. Accessed 18Dec2020. ³Wan L and Anderson D. Viruses in bats and potential spillover to animals and humans. Current Opinion in Virology 2019;34:79-89. ⁴Ochani R, et al. Nipah virus – the rising epidemic: a review. Le Infezioni in Medicina 2019;2:117-129.

Nipah vaccine (mRNA-1215) overview

Moderna/NIH collaboration

- Nomination of mRNA-1215 to test a Nipah vaccine candidate in humans
- mRNA vaccine co-developed by Moderna/NIH-VRC
- Phase 1 clinical testing for pandemic preparedness



Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.